A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors

The IGF pathway has been implicated in the regulation of neuroendocrine tumor (NET) growth, and preliminary studies suggested that ganitumab (AMG 479), a human MAB against IGF1R, may have antitumor activity in this setting. We performed a two-cohort phase II study of ganitumab in patients with metas...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Strosberg, J R, Chan, J A, Ryan, D P, Meyerhardt, J A, Fuchs, C S, Abrams, T, Regan, E, Brady, R, Weber, J, Campos, T, Kvols, L K, Kulke, M H
Format: Artigo
Sprog:Inglês
Udgivet: 2013
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4029434/
https://ncbi.nlm.nih.gov/pubmed/23572164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-12-0390
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker